Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Maveropepimut-S Plus Pembrolizumab and Cyclophosphamide Shows Early Promise in R/R DLBCL

February 13th 2023

The combination of maveropepimut-S, pembrolizumab, and intermittent low-dose cyclophosphamide elicited responses in patients with relapsed or refractory diffuse large B-cell lymphoma, according to preliminary findings from the phase 2b VITALIZE trial.

Treatment Options: Steroid-Refractory GvHD

February 10th 2023

Experts define and review treatment options for patients with chronic GvHD that are also steroid refractory.

Treatment Options for Chronic GvHD

February 10th 2023

Comprehensive discussion into the available treatment options for patients that present with chronic GvHD.

Brexucabtagene Autoleucel Elicits OS Benefit in Relapsed/Refractory B-ALL

February 9th 2023

The CAR T-cell therapy brexucabtagene autoleucel produced a median overall survival of 26 months in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Teclistamab Demonstrates Exciting Efficacy in Relapsed or Refractory Multiple Myeloma

February 9th 2023

Alfred L. Garfall, MD, discusses the durability of responses teclistamab elicited in the MajesTEC-1 trial and how this agent will change the treatment regimen for relapsed/refractory multiple myeloma.

The Impact of p53 Mutations and 5q Deletions on Lower-Risk MDS Treatment Response

February 9th 2023

Dr Komrokji leads a discussion on emerging data on how p53 mutations and chromosome 5q deletions may affect prognosis, treatment response, and outcomes for patients with MDS.

Case 1: Expert Panelist Commentary

February 9th 2023

Expert panelists reflect on the case presented by Dr Garcia-Manero and share their unique perspectives on how they might have approached treatment and followup for this patient in their own practice.

Unpacking Data From Pivotal Trials in Multiple Myeloma: Exploring Key Takeaways from the DETERMINATION Trial

February 8th 2023

In this fifth episode of OncChats: Unpacking Data From Pivotal Trials in Multiple Myeloma, Hamza Hashmi, MD, reviews the implications of up-front vs delayed transplant on survival, quality of life, and risk of secondary malignancies in newly diagnosed, multiple myeloma.

Remaining Unmet Needs and Additional Ongoing Trials in MF

February 8th 2023

Dr Komrokji summarizes the remaining unmet needs in the treatment of MF, including suboptimal responses to JAK2 inhibitors, and comments on data from ongoing trials that may address these needs.

Myelofibrosis: Treatment Landscape and Recent Data Updates on JAK2 Inhibitors

February 8th 2023

A comprehensive review of the treatment landscape for myelofibrosis (MF) and recent ASCO and ASH data updates on JAK2 inhibitors.

Crovalimab Demonstrates Noninferiority to Eculizumab in Phase 3 COMMODORE 2 Trial in PNH

February 7th 2023

Treatment with crovalimab led to disease control through transfusion avoidance and control of hemolysis in patients with paroxysmal nocturnal hemoglobinuria who have not been previously treated with complement inhibitors.

Tumor Lysis Syndrome: Unmet Needs and Future Directions in Care

February 7th 2023

Closing out their discussion on tumor lysis syndrome management, James Short, MD, and John Reagan, MD, highlight unmet needs and future evolutions in the treatment landscape.

Frontline Therapy for Patients With AML and FLT3 Alterations

February 7th 2023

Expert perspectives on the emergence of FLT3-targeted therapies and their role in the first-line setting of acute myeloid leukemia management.

TLS Management in Academic vs Community Centers of Care

February 7th 2023

A brief review of the differences that might be observed between tumor lysis syndrome management in an academic versus community setting.

Role of Intensive Chemotherapy in Young, Fit Patients With AML

February 7th 2023

Centering focus on first-line treatment modalities, panelists highlight the ongoing role of intensive chemotherapy in the management of AML.

Revumenib Drives Durable CR/CRh Rates in KMT2A-rearranged and NMP1-mutant AML

February 3rd 2023

Revumenib resulted in deep response rates, facilitating subsequent transplant in patients with KMT2A-rearranged or NMP1-mutant, relapsed/refractory acute myeloid leukemia.

Defining Chronic Graft vs Host Disease (GvHD)

February 3rd 2023

Panel of oncologists define in chronic GvHD and review the typical presentation of a patient.

Novel Agents in Acute GvHD

February 3rd 2023

Experts discuss new and exciting agents and combinations that are on the horizon for patients with acute GvHD.

Dr. Wang on Expanding the Role of MRD Testing in AML

February 2nd 2023

Eunice Wang, MD, discusses the utility of minimal residual disease testing in hematologic malignancies and challenges associated with expanding its role in clinical practice for acute myeloid leukemia.

Rosenthal Discusses the Need for Standardized Care in AYA Hodgkin Lymphoma

February 2nd 2023

Dr Rosenthal discusses the care of adolescent and young adult patients with Hodgkin lymphoma, the discrepancies between pediatric and adult oncologists that result in differing treatment approaches, and common concerns these patients have as they navigate their diagnosis and treatment alongside other life changes.